BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 17728106)

  • 1. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
    Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
    Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.
    Riedel M; Müller N; Spellmann I; Engel RR; Musil R; Valdevit R; Dehning S; Douhet A; Cerovecki A; Strassnig M; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Oct; 257(7):402-12. PubMed ID: 17629725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].
    Mayoral F; Montejo AL; Bousoño M; González-Torres MA; Olivares JM; Ros S; Sanjuán J; Escobar R; Lara N
    Actas Esp Psiquiatr; 2006; 34(1):7-15. PubMed ID: 16525900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings.
    Velligan DI; Prihoda TJ; Sui D; Ritch JL; Maples N; Miller AL
    J Clin Psychiatry; 2003 May; 64(5):524-31. PubMed ID: 12755654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
    Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA;
    Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.
    Robles O; Zabala A; Bombín I; Parellada M; Moreno D; Ruiz-Sancho A; Arango C
    Schizophr Bull; 2011 Mar; 37(2):405-15. PubMed ID: 19706697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.
    Voruganti L; Cortese L; Owyeumi L; Kotteda V; Cernovsky Z; Zirul S; Awad A
    Schizophr Res; 2002 Oct; 57(2-3):201-8. PubMed ID: 12223251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia.
    Kaneda Y; Kawamura I; Fujii A; Ohmori T
    Neuro Endocrinol Lett; 2004; 25(1-2):135-40. PubMed ID: 15159697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial.
    Johnsen E; Jørgensen HA; Kroken RA; Løberg EM
    Eur Psychiatry; 2013 Mar; 28(3):174-84. PubMed ID: 22153730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.
    Yamashita H; Mori K; Nagao M; Okamoto Y; Morinobu S; Yamawaki S
    J Clin Psychiatry; 2004 Nov; 65(11):1525-30. PubMed ID: 15554767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.
    Torrent C; Martinez-Arán A; Daban C; Amann B; Balanzá-Martínez V; del Mar Bonnín C; Cruz N; Franco C; Tabarés-Seisdedos R; Vieta E
    Compr Psychiatry; 2011; 52(6):613-22. PubMed ID: 21295774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.